article thumbnail

Deliberate AI Announces its Depression and Anxiety Model, AI-COA™, is the First AI/ML Initiative to Be Accepted into the FDA’s ISTAND Pilot Program to Advance Drug Development

Digital Health Global

Under the program, Deliberate AI’s assessment tool for anxiety and depression, the AI-generated Clinical Outcome Assessment or AI-COA , will receive support to become a qualified drug development tool (DDT). Global experts have also expressed support for Deliberate AI’s innovative approach.

article thumbnail

Palantir and Healthcare: What could the future hold?

Lloyd Price

Historically, Palantir has worked with healthcare organizations to leverage its data integration and analytics capabilities to improve clinical research, public health, and healthcare operations. Overall, Palantir's software is helping to improve patient care, accelerate research, and improve drug development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

6 challenges healthtech can help us tackle – Pt.2

Digital Health Global

Wearable monitoring devices, genomics, and AI play vital roles in this transformation, enabling personalized interventions and collective health data sharing for research. Drug development The traditional drug discovery process is characterized by its protracted timeline, high costs, and significant attrition rates among drug candidates.

article thumbnail

Let’s Save the Date and Make Patient Engagement Official in 2022

Society for Participatory Medicine

Now that these innovations are here to stay (or so we hope), are we circling back to ensure adequate understanding of what is needed to achieve their full potential for public health improvement? She was the patient keynote speaker at DPHARM 2021 and is a HIMSS Digital Health Influencer.

BioTech 107
article thumbnail

Q&A with Rami Rajab and Inna Nadelwais, Mecomed

Healthcare Innovation Consortium

Inna: We align with the World Health Organisation in that AMR is one of the top 10 global public health threats facing humanity. The pipeline for new antibiotics is limited, which is partly due to how new drug development is funded.

BioTech 60
article thumbnail

FDA Gives Diabetes Treatments Low Priority

Insulin Nation

Even though health officials readily admit that diabetes is an urgent public health problem, a new diabetes medicine or device usually finds itself in ninth position on the FDA docket for a pre-market clearance. To understand why requires an understanding of the history of the FDA, and its limitations.

article thumbnail

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

Digital Health Global

We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.” 2 Digital health is a large (+$900bn by 2032) and growing (13.6%